Tenderwize
Zurück zur Suche

Open-house rebate agreement for Anakinra

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Anakinra, ATC L04AC03

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive rebate agreements for the active substance Anakinra, ATC L04AC03.
  • Open-house model with identical, non-negotiable contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Anakinra (ATC L04AC03) offered by AOK Bayern to all interested pharmaceutical companies meeting the stated suitability requirement. This is explicitly described as an open-house model, not a competitive award procedure, with identical non-negotiable contract terms and no selection among bidders. Contracting is possible during the term, with the earliest start on 2025-10-01 and latest contract conclusion by 2027-08-03. Submission can be paper or electronic via DTVP, but the contract documents must be submitted through the communication area, not the offer area.

Risiken

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The contract must be submitted signed; signatory authority must be evidenced by the commercial register extract or a power of attorney must be provided.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Anakinra

Single lot for non-exclusive pharmaceutical rebate agreements concerning Anakinra, ATC L04AC03. Scope is pharmaceutical supplies under an open-house model; contract terms are pre-set and not individually negotiable. The lot is for Germany, with performance in Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Sep 2025 - Sep 2027

Kategorie

Pharmaceutical products

Frist

Deadline Aug 03, 2027

Vergabedetails

Veröffentlichungsdatum
13 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
532705-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30